Akademik Portal | Prof. Dr. Özden Altundağ Özgeçmiş Sayfası

Yükleniyor

Prof. Dr. Özden Altundağ

Tıbbi Onkoloji Bilim Dalı
oaltundag[at]baskent.edu.tr
0(312) 246 66 66

H-İndeks 16

Birleşmiş Milletler Sürdürülebilir Kalkınma Amaçları

Toplam Yayın : 1

Yayın Bilgileri


1 Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer., NEW ENGLAND JOURNAL OF MEDICINE, 386(5), 2022 Prof. Dr. Özden Altundağ
2 Survival impact of number of removed para-aortic lymph nodes in stage I epithelial ovarian cancer, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 305(2), 2022 Doç. Dr. Emre Günakan, Doç. Dr. Hüseyin Akıllı, Araş.Gör.Dr. Atacan Timuçin Kara, Prof. Dr. Özden Altundağ, Prof. Dr. Asuman Nihan Haberal Reyhan, Prof. Dr. Mehmet Mutlu Meydanlı, Prof. Dr. Ali Ayhan
3 Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer., JOURNAL OF EVOLUTION EQUATIONS, 385(20), 2022 Prof. Dr. Özden Altundağ
4 Complications of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: An evaluation of 100 cases, INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 156(3), 2021 Prof. Dr. Ali Haberal, Doç. Dr. Hüseyin Akıllı, Prof. Dr. Özden Altundağ, Prof. Dr. Ülkü Esra Kuşcu, Cagatay Taskiran, Prof. Dr. Ali Ayhan, Emre Gunakan
5 Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant., Experimental and Clinical Transplantation, 18(2), 2020 Prof. Dr. Özden Altundağ
6 Surgical management and outcomes of metastatic tumors to the ovaries, EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 40(5), 2019 Prof. Dr. Ali Haberal, Prof. Dr. Asuman Nihan Haberal Reyhan, Prof. Dr. Ali Ayhan, Doç. Dr. Hüseyin Akıllı, Prof. Dr. Özden Altundağ, Doç. Dr. Samed Rahatlı
7 Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial., LANCET, 393(1018), 2019 Prof. Dr. Özden Altundağ
8 Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer., Journal of BUON, 23(7), 2018 Prof. Dr. Özden Altundağ
9 The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer., ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 5(0), 2017 Prof. Dr. Özden Altundağ
10 Treatment of Lymph Node?Negative, Early-Stage HER2-Positive Breast Cancer, JOURNAL OF CLINICAL ONCOLOGY, 34(6), 2016 Prof. Dr. Arzu Oğuz, Gül Sema Keskin, Dilşen Çolak, Prof. Dr. Özden Altundağ, Prof. Dr. Zafer Akçalı
11 ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up., INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 26(1), 2016 Prof. Dr. Özden Altundağ
12 ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, 27(1), 2016 Prof. Dr. Özden Altundağ
13 Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes, Journal of BUON, 21(5), 2016 Prof. Dr. Özden Altundağ
14 ESMO-ESGO-ESTRO concensus confenece on endometrial cancer, RADIOTHERAPY AND ONCOLOGY, 7(1), 2016 Prof. Dr. Özden Altundağ
15 Trastuzumab in metastatic breast cancer after complete remission: How long is enough?, MEDICAL ONCOLOGY, 32(8), 2015 Prof. Dr. Arzu Oğuz, Doç. Dr. Samed Rahatlı, Prof. Dr. Özden Altundağ, Kadri Altundağ
16 . Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study., GYNECOLOGIC ONCOLOGY, 131(3), 2014 Prof. Dr. Özden Altundağ
17 The relationship between thyroid volume and malignant thyroid disease, MEDICAL ONCOLOGY, 31(1), 2014 Prof. Dr. Özden Altundağ
18 Weekly cisplatin versus standard three-weekly cisplatin in concurrent, AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS, 1(5), 2011 Prof. Dr. Özden Altundağ


1 Combined versus sequential antracycline and taxane adjuvant regimens in triple negative breast cancer patients, ASCO, 12.05.2016 Gül Sema Keskin, Prof. Dr. Arzu Oğuz, Prof. Dr. Zafer Akçalı, Prof. Dr. Özden Altundağ
2 Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes., american society of clinical oncology (ASCO), 30.05.2014 Taner Babacan, Prof. Dr. Arzu Oğuz, Prof. Dr. Özden Altundağ